Cue Biopharma (CUE) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Cue Biopharma (CUE) over the past year, gaining 75.7% versus a loss of 13.2%. Over five years, ORMP leads with a -81.0% price change compared with -94.1% for CUE. Oramed Pharmaceuticals is the larger company by market cap ($174.7 million vs $162.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | ORMP |
|---|---|---|
| Share price | $22.33 | $4.20 |
| Market cap | $162.21M | $174.71M |
| 1-day change | -0.80% | -3.89% |
| YTD return | +144.04% | +47.37% |
| 1-year return | -13.25% | +75.73% |
| 5-year return | -94.09% | -80.96% |
| P/E ratio (TTM) | — | 1.02 |
| EPS (TTM) | $-29.59 | $4.13 |
| Dividend yield | 0.00% | 5.92% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $5.47 |
| 52-week low | $4.98 | $2.09 |
| Distance from 52-week high | -50.92% | -23.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +294.09% | +66.67% |
| Average volume | 267.15K | 190.50K |
| Shares outstanding | 7.26M | 41.60M |
| Employees | 29 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed CUE by 89.0 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.92% vs 0.00%).
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
CUE vs ORMP FAQ
Which is bigger, Cue Biopharma or Oramed Pharmaceuticals?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $174.71M compared with $162.21M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or ORMP?
ORMP returned +75.73% over the past 12 months, compared with -13.25% for CUE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cue Biopharma or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.92%, while Cue Biopharma does not currently pay a regular dividend.
Are Cue Biopharma and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.